Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Authors
Keywords
-
Journal
MOLECULES
Volume 27, Issue 12, Pages 3798
Publisher
MDPI AG
Online
2022-06-14
DOI
10.3390/molecules27123798
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune-related adverse events and the balancing act of immunotherapy
- (2022) Michael Conroy et al. Nature Communications
- Autophagy as a Therapeutic Target of Natural Products Enhancing Embryo Implantation
- (2022) Hyerin Park et al. Pharmaceuticals
- Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives
- (2022) Md. Rahman et al. Biology-Basel
- Natural therapeutics and nutraceuticals for lung diseases: Traditional significance, phytochemistry, and pharmacology
- (2022) Md. Mominur Rahman et al. BIOMEDICINE & PHARMACOTHERAPY
- Multifunctional Therapeutic Approach of Nanomedicines against Inflammation in Cancer and Aging
- (2022) Md. Mominur Rahman et al. Journal of Nanomaterials
- B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
- (2022) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
- (2022) T. Anders Olsen et al. Frontiers in Endocrinology
- Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
- (2021) Josefien W. Hommes et al. Frontiers in Oncology
- Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a Key Gut Bacterium
- (2021) Raluca Anca Corb Aron et al. Microorganisms
- Precision oncology: a clinical and patient perspective
- (2021) Ulrik N Lassen et al. Future Oncology
- Immune‐Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
- (2021) Dylan J. Martini et al. ONCOLOGIST
- Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?
- (2021) Elisa Giannetta et al. Frontiers in Endocrinology
- Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme
- (2021) Tapan Behl et al. Cancers
- Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
- (2021) Bianca D. Santomasso et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
- (2021) Jia Luo et al. Journal of Thoracic Oncology
- Berberine as a Potential Anticancer Agent: A Comprehensive Review
- (2021) Abdur Rauf et al. MOLECULES
- Immune‐Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration‐Approved Indications for Immunotherapy
- (2020) Satya Das et al. ONCOLOGIST
- iRECIST: how to do it
- (2020) Thorsten Persigehl et al. CANCER IMAGING
- Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions
- (2020) Malek Kreidieh et al. Biomed Research International
- Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
- (2020) Manuela Tiako Meyo et al. Cancers
- Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
- (2020) Jesus Vera Aguilera et al. MELANOMA RESEARCH
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer
- (2020) Shamir Cassim et al. Cancers
- Immunothérapie des cancers bronchiques non à petites cellules métastatiques, de la première ligne à la résistance et sa prise en charge
- (2020) Clémence Basse et al. BULLETIN DU CANCER
- The non-invasive assessment of hepatic fibrosis
- (2020) Gina Gheorghe et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Strategies for improving the management of immune-related adverse events
- (2020) Aung Naing et al. Journal for ImmunoTherapy of Cancer
- Current advancements and future perspectives of immunotherapy in colorectal cancer research
- (2020) Chandra Kishore et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
- (2019) Marco Gallo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Immune checkpoint inhibitor-induced colitis: A comprehensive review
- (2019) Aniruddh Som et al. World Journal of Clinical Cases
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Management of immune related adverse events induced by immune checkpoint inhibition
- (2019) Andreas Teufel et al. CANCER LETTERS
- Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells
- (2019) T. Alissafi et al. JOURNAL OF AUTOIMMUNITY
- BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
- (2019) Omar Hasan Ali et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
- (2019) Sophia C Weinmann et al. RHEUMATOLOGY
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- New insight in endocrine-related adverse events associated to immune checkpoint blockade
- (2019) Giusy Elia et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
- (2019) Yi-He Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response
- (2019) Shamir Cassim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
- (2018) Dipti M Karamchandani et al. JOURNAL OF CLINICAL PATHOLOGY
- Scleroderma-like skin changes induced by checkpoint inhibitor therapy
- (2018) B. Joel Tjarks et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- (2018) Eleonora De Martin et al. JOURNAL OF HEPATOLOGY
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
- (2018) Adriana T. Lopez et al. ONCOLOGIST
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
- (2018) Andrew L Mammen et al. ANNALS OF THE RHEUMATIC DISEASES
- Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.
- (2018) Cathy Yi Xia et al. JOURNAL OF CLINICAL ONCOLOGY
- Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
- (2018) Elizabeth Dudnik et al. LUNG CANCER
- Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer
- (2018) Muhammad Khan et al. MEDICINE
- Rheumatic immune-related adverse events from cancer immunotherapy
- (2018) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
- (2018) Sabina Sandigursky et al. Current Rheumatology Reports
- Immune Checkpoint Inhibitor-Associated Colits and Hepatitis
- (2018) Haritha G. Reddy et al. Clinical and Translational Gastroenterology
- A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
- (2018) Philip Friedlander et al. Journal for ImmunoTherapy of Cancer
- Tildrakizumab: A Review of Phase II and III Clinical Trials
- (2018) Sree S. Kolli et al. ANNALS OF PHARMACOTHERAPY
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
- (2018) Juliane Gust et al. CNS DRUGS
- Immune-related adverse events of immune checkpoint inhibitors: a brief review
- (2018) G. Myers Current Oncology
- Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia
- (2018) Xavier Thomas et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
- (2018) Michael J Flynn et al. HEPATOLOGY
- Induced CD20 expression on B-cell malignant cells heightened the cytotoxic activity of chimeric antigen receptor engineered T cells
- (2018) Yingxi Xu et al. HUMAN GENE THERAPY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash
- (2018) Pradnya D. Patil et al. ONCOLOGIST
- The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
- (2017) Emma S Scott et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia
- (2017) Jun Liu et al. Immunotherapy
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
- (2017) Takeo Fujii et al. INVESTIGATIONAL NEW DRUGS
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
- (2017) Cynthia L. Gay et al. JOURNAL OF INFECTIOUS DISEASES
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis
- (2017) Sheng Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Is autoimmunity the Achilles' heel of cancer immunotherapy?
- (2017) Carl H June et al. NATURE MEDICINE
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Immune‑related adverse events during anticancer immunotherapy: Pathogenesis and management (Review)
- (2017) Stefania Stucci et al. Oncology Letters
- Excellent response to chemotherapy post immunotherapy
- (2017) Ashish D. Dwary et al. Oncotarget
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Immune-mediated respiratory adverse events of checkpoint inhibitors
- (2016) Samer Tabchi et al. CURRENT OPINION IN ONCOLOGY
- Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
- (2016) Omar Abdel-Rahman et al. Future Oncology
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Surrogate End Points and Their Validation in Oncology Clinical Trials
- (2016) Fengmin Zhao JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
- (2016) Elisa González-Rodríguez et al. ONCOLOGIST
- Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
- (2016) Paola Savoia et al. Human Vaccines & Immunotherapeutics
- Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
- (2016) Yumi Nonomura et al. OncoImmunology
- Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
- (2016) Masatoshi Kudo Liver Cancer
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Ipilimumab-associated Hepatitis
- (2015) Melanie Johncilla et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- Genetic analysis reveals diversity and genetic relationship among Trichoderma isolates from potting media, cultivated soil and uncultivated soil
- (2015) Abdullah M. Al-Sadi et al. BMC MICROBIOLOGY
- Infliximab for IPILIMUMAB-Related Colitis--Letter
- (2015) E. Arriola et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- The place of PD-1 inhibitors in melanoma management
- (2015) Samantha Bowyer et al. LANCET ONCOLOGY
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
- (2015) Ninh M. La-Beck et al. PHARMACOTHERAPY
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
- (2015) S. H. Tirumani et al. Cancer Immunology Research
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
- (2013) Francesco Torino et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia
- (2013) Sascha Dietrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
- (2013) Vafa Shahabi et al. Journal of Translational Medicine
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
- (2010) Katsuhiko Nosho et al. JOURNAL OF PATHOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
- (2009) Troy Dillard et al. Pituitary
- Survival for Patients With Invasive Cutaneous Melanoma Among Ethnic Groups: The Effects of Socioeconomic Status and Treatment
- (2007) Jason A. Zell et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now